PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 23, 2026Journal of Pediatric Gastroenterology and Nutrition0 citationsOpen Access

The pharmacokinetics and safety of vonoprazan in adolescents and children with gastroesophageal reflux disease

View Full Paper
DMDarcy J. MulfordLi Creative Technologies (United States)DGDavid A. GremseUniversity of South AlabamaYCYu‐Ming ChangLi Creative Technologies (United States)

Key Points

  • To evaluate the pharmacokinetics and safety of vonoprazan in adolescents and children with gastroesophageal reflux disease.
  • Analyzed pharmacokinetic data of vonoprazan in a pediatric population.
  • Compared exposure levels between adolescents, children, and adults.
  • Assessed safety and tolerability of standard doses.
  • Vonoprazan exposure in adolescents and children mirrored that found in adults.
  • Both 10 mg and 20 mg doses were deemed appropriate for pediatric use.
  • Safety profiles were consistent with adult findings.

Abstract

Exposures of vonoprazan in adolescents and children were nearly identical to exposures observed in adults, confirming the appropriateness of vonoprazan 10 and 20 mg doses in a pediatric population.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mulford et al. (2026) studied this question.

synapsesocial.com/papers/699ba0a772792ae9fd8708cehttps://doi.org/10.1002/jpn3.70368
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Development and Use of a Population Pharmacokinetic Model for Characterizing the Pharmacokinetics of Vonoprazan in Pediatric Patients2026
  2. 2Real‐World Safety of Vonoprazan in Patients and Symptom Outcomes in Patients With Reflux Esophagitis in China: A Prospective, Non‐Interventional Study ( <scp>VIEW</scp> )2026
  3. 3Vonoprazan: a promising advancement in proton pump inhibitor therapy2024 · 4 citations
  4. 4Long-term safety and effectiveness of vonoprazan as maintenance therapy for reflux esophagitis in Japan: a 12-month post-marketing surveillance study2026 · 1 citations
  5. 5Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study2017 · 123 citations